Levinson Kimberly, Dorigo Oliver, Rubin Krista, Moore Kathleen
1 The Kelly Gynecologic Oncology Service, Johns Hopkins School of Medicine, Baltimore, MD.
2 Stanford University, Palo Alto, CA.
Am Soc Clin Oncol Educ Book. 2019 Jan;39:e126-e140. doi: 10.1200/EDBK_237967. Epub 2019 May 17.
Immunotherapy, mainly in the form of immune checkpoint inhibitors (ICIs), has been transformative in both solid tumor and hematologic malignancies. Patients with previously terminal illnesses have experienced profound responses of great durability with these agents, fueling excitement among patients and providers regarding their use. Unfortunately, the gains seen in some solid tumors have not been replicated in a large percentage of patients with gynecologic cancer. This review focuses on the clinical benefits seen to date, toxicities and management when using ICIs, ways to improve prediction of who should receive immunotherapy, and a discussion of next-generation immunotherapy with cellular therapeutics and how these might relate to gynecologic cancers.
免疫疗法，主要是以免疫检查点抑制剂（ICIs）的形式，在实体瘤和血液系统恶性肿瘤的治疗中都带来了变革。患有先前晚期疾病的患者使用这些药物后出现了持久且显著的反应，这让患者和医疗服务提供者对其使用充满期待。不幸的是，在一些实体瘤中看到的疗效并未在很大比例的妇科癌症患者中得到重现。本综述重点关注了迄今为止所观察到的临床益处、使用ICIs时的毒性及管理、改善预测哪些患者应接受免疫治疗的方法，以及对细胞疗法下一代免疫治疗的讨论，以及这些疗法与妇科癌症的关系。
